Clinical trials: CTLA-4
Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Title: A Study of Cadonilimab Combined with Capecitabine After Surgery for Mixed Type Liver Cancer This is a phase II clinical trial.
- Trial name
- NCT07243951
- Testing
- Cadonilimab, Capecitabine
- Volunteers
- 75 people
- Sponsor
- Shanghai Zhongshan Hospital
Platinum-resistant Recurrent Ovarian Cancer
A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT06509971
- Testing
- QL1706
- Volunteers
- 39 people
- Sponsor
- West China Second University Hospital
Prostate Cancer
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
The purpose of this study is to find out what effects taking ipilimumab, as an immediate or delayed treatment, following completion of sipuleucel-T (SipT) treatment, has on patients and their prostate cancer.
- Trial name
- NCT01804465
- Testing
- SipT Treatment, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04444167
- Testing
- AK104, Lenvatinib
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Akeso
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies the side effects and best dose of ipilimumab, nivolumab, and radiation therapy and how well they work in treating patients with advanced human papillomavirus (HPV) positive oropharyngeal squamous cell…
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma
- Trial name
- NCT03799445
- Testing
- Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer.
- Trial name
- NCT01740401
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Liver Cancer
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of…
- Trial name
- NCT03949231
- Testing
- PD1/PDL1 inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Nasopharyngeal Carcinoma
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior…
- Trial name
- NCT04220307
- Testing
- AK104
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Akeso
Lupus Nephritis, Lupus Erythematosus, Systemic
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is…
- Trial name
- ACCESS (NCT00774852)
- Testing
- abatacept, cyclophosphamide, azathioprine
- Where
- 23 sites in United States, Mexico
- Volunteers
- 137 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Solid Tumors, Melanoma
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
- Trial name
- NCT04172454
- Testing
- AK104
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Esophageal Squamous Cell Carcinoma
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with…
- Trial name
- NCT05490719
- Testing
- QL1706
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Melanoma
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) Monotherapy in Patients with Unresectable/Metastatic Melanoma.
- Trial name
- NCT03472027
- Testing
- BCD-145
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Advanced Cancers
Ipilimumab and Lenalidomide in Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of the combination of Yervoy® (ipilimumab) with Revlimid® (lenalidomide) that can be given to patients with advanced cancer.
- Trial name
- NCT01750983
- Testing
- Ipilimumab, Lenalidomide
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single…
- Trial name
- NCT00050596
- Testing
- MDX-010 / MDX-010 + Docetaxel
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Advanced Sarcoma, Metastatic Sarcoma
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma…
- Conditions
- Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT05448820
- Testing
- YH001, Envafolimab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Cancer
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid…
- Trial name
- ICONIC (NCT02904226)
- Testing
- JTX-2011, Nivolumab, Ipilimumab
- Where
- 16 sites in United States
- Volunteers
- 242 people
- Sponsor
- Jounce Therapeutics, Inc.
Advanced Clear Cell Renal Cell Carcinoma
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell…
- Trial name
- eVOLVE-RCC02 (NCT07000149)
- Testing
- Volrustomig, Casdatifan
- Where
- 3 sites in Australia, South Korea
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Metastatic Non-small Cell Lung Cancer, NSCLC
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
This is an open-label, multicenter, 2-arm study to evaluate the safety and preliminary efficacy of the addition of a vaccine therapy to 1 or 2 checkpoint inhibitors for NSCLC.
- Trial name
- NCT03164772
- Testing
- Durvalumab, Tremelimumab, BI 1361849
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Ludwig Institute for Cancer Research
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.